The present disclosure relates to novel ester forms of medroxyprogesterone process for their preparation and pharmaceutical compositions comprising the same. The present disclosure also relates to use of the novel ester forms in hormonal therapies such as, for example, contraception, hormone replacement therapy, endometriosis, etc.

The present invention relates to an inorganic-organic hybrid compound as ionic compound, composed of an inorganic cation and of an organic active ingredient anion and also, optionally, of an organic fluorescent dye anion.